{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:18:19Z","timestamp":1792275499686,"version":"4.4.0"},"reference-count":19,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2 inhibitors), initially developed for glycemic control in type 2 diabetes, have demonstrated robust cardiovascular and renal benefits. Emerging evidence suggests that these agents may also affect valvular pathobiology, particularly in degenerative aortic stenosis (AS), through anti-inflammatory and antifibrotic mechanisms. Objectives: This study evaluated whether SGLT2 inhibitor use is associated with improved clinical outcomes in degenerative AS, including all-cause mortality and the need for SAVR or TAVR, recognizing that these endpoints represent surrogate rather than direct measures of valve hemodynamic progression. Methods: A retrospective cohort analysis was conducted using TriNetX, a federated electronic medical record-based research network. Diagnoses are captured using ICD-9\/ICD-10-CM codes and medications using ATC codes. Adults with non-rheumatic AS were stratified by SGLT2 inhibitors use. Propensity score matching (1:1) was performed to balance baseline characteristics between treated and untreated groups (n = 10,912 per group). Primary outcomes included all-cause mortality, TAVR, and SAVR during follow-up. Echocardiographic parameters (AVA, Vmax, mean gradient) were not systematically available. Results: After adjustment for comorbidities, SGLT2 inhibitor use was independently associated with lower all-cause mortality (6.15% vs. 9.34% HR 0.595; 95% CI 0.552\u20130.641; p &lt; 0.001), TAVR (2.81% vs. 2.89% HR 0.835; 95% CI 0.746\u20130.934; p = 0.002), SAVR (1.28% vs. 1.90% HR 0.514; 95% CI 0.442\u20130.599; p &lt; 0.001), cardiac arrest (0.82% vs. 1.21% HR 0.71; 95% CI 0.582\u20130.867; p &lt; 0.001), and end-stage kidney disease (0.40% vs. 1.0% HR 0.292; 95% CI 0.222\u20130.384; p &lt; 0.001). Although these associations may suggest slower disease progression, interpretation is limited by the lack of systematic echocardiographic follow-up. Conclusions: In addition to their established benefits in heart failure and renal protection, SGLT2 inhibitors may have valve-preserving effects in degenerative AS. Because true hemodynamic progression could not be evaluated, these results should be viewed as associations with surrogate clinical endpoints. Prospective studies with standardized imaging are required to determine whether SGLT2 inhibition can directly alter the course of this currently untreatable disease<\/jats:p>","DOI":"10.3390\/jcm15020714","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:35:38Z","timestamp":1768487738000},"page":"714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-3041","authenticated-orcid":false,"given":"Olivier","family":"Morel","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nouvel H\u00f4pital Civil, Strasbourg University Hospital, 67098 Strasbourg, France"},{"name":"UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, 67000 Strasbourg, France"},{"name":"GERCA Groupe pour l\u2019Enseignement, la Pr\u00e9vention et la Recherche Cardiologique en Alsace, 67200 Strasbourg, France"},{"name":"Hano\u00ef Medical University, Hanoi 100000, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Guglieri","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, 37000 Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Trimaille","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nouvel H\u00f4pital Civil, Strasbourg University Hospital, 67098 Strasbourg, France"},{"name":"UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, 67000 Strasbourg, France"},{"name":"GERCA Groupe pour l\u2019Enseignement, la Pr\u00e9vention et la Recherche Cardiologique en Alsace, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-1466","authenticated-orcid":false,"given":"Benjamin","family":"Marchandot","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nouvel H\u00f4pital Civil, Strasbourg University Hospital, 67098 Strasbourg, France"},{"name":"UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, 67000 Strasbourg, France"},{"name":"GERCA Groupe pour l\u2019Enseignement, la Pr\u00e9vention et la Recherche Cardiologique en Alsace, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Bisson","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, 37000 Tours, France"},{"name":"Inserm U1327 ISCHEMIA \u201cMembrane Signalling and Inflammation in Reperfusion Injuries\u201d, Universit\u00e9 de Tours, 37000 Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Granier","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nouvel H\u00f4pital Civil, Strasbourg University Hospital, 67098 Strasbourg, France"},{"name":"UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, 67000 Strasbourg, France"},{"name":"GERCA Groupe pour l\u2019Enseignement, la Pr\u00e9vention et la Recherche Cardiologique en Alsace, 67200 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-9287","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Schini-Kerth","sequence":"additional","affiliation":[{"name":"UR 3074 Translational Cardiovascular Medicine, CRBS, University of Strasbourg, 67000 Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Bernard","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, 37000 Tours, France"},{"name":"Inserm U1327 ISCHEMIA \u201cMembrane Signalling and Inflammation in Reperfusion Injuries\u201d, Universit\u00e9 de Tours, 37000 Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1658","authenticated-orcid":false,"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Facult\u00e9 de M\u00e9decine, Universit\u00e9 Fran\u00e7ois Rabelais, 37000 Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations","volume":"81","author":"Usman","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2020.11.029","article-title":"The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure","volume":"77","author":"Goldberg","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacbts.2024.02.012","article-title":"Human Aortic Stenotic Valve-Derived Extracellular Vesicles Induce Endothelial Dysfunction and Thrombogenicity Through AT1R\/NADPH Oxidases\/SGLT2 Pro-Oxidant Pathway","volume":"9","author":"Hmadeh","year":"2024","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cvr\/cvac192","article-title":"Aortic stenosis and the haemostatic system","volume":"119","author":"Trimaille","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejhf.3145","article-title":"Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study","volume":"26","author":"Scisciola","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Trimaille, A., Hmadeh, S., Kikuchi, S., Mroueh, A., Carmona, A., Marchandot, B., Beras, F., Truong, D.P., Vu, M.C., and Granier, A. (2025). Detrimental effects of plasma from patients with severe aortic stenosis on valvular endothelial cells: Role of proinflammatory cytokines and factor Xa. J. Am. Heart Assoc., e041701.","DOI":"10.1161\/JAHA.125.041701"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/dom.16238","article-title":"GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity","volume":"27","author":"Bucci","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.hrthm.2024.11.044","article-title":"Risk of death and thrombosis in patients admitted to the emergency department with supraventricular tachycardias","volume":"22","author":"Bucci","year":"2024","journal-title":"Heart Rhythm. Off. J. Heart Rhythm. Soc."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Morel, O., Granier, A., Lochon, L., Trimaille, A., Bisson, A., Marchandot, B., Bernard, A., and Fauchier, L. (2025). Association of SGLT2 Inhibitors with Mortality and Bioprosthesis Valve Failure After TAVR: A Propensity-Matched Cohort Study. J. Clin. Med., 14.","DOI":"10.2139\/ssrn.5336439"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jcin.2022.06.022","article-title":"Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A Systematic Review and Meta-Analysis","volume":"15","author":"Coisne","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10741-024-10467-x","article-title":"Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action","volume":"30","author":"Kamperidis","year":"2025","journal-title":"Heart Fail. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","article-title":"Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation","volume":"392","author":"Rossello","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00109-025-02615-z","article-title":"Dapagliflozin inhibits TGF-beta-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration","volume":"104","author":"Sato","year":"2025","journal-title":"J. Mol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jcin.2024.11.036","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis","volume":"18","author":"Shah","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101750","DOI":"10.1016\/j.jacadv.2025.101750","article-title":"The Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Bioprosthetic Aortic Valve Degeneration","volume":"4","author":"Abbas","year":"2025","journal-title":"JACC Adv."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Obeidat, O., Alayyat, A., Naser, A., Ghanem, F., Jabri, A., Brankovic, M., Jiao, T., Ruzieh, M., Haddad, A., and Alexy, T. (2025). Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: A propensity-matched analysis. Rev. Esp. De Cardiol.","DOI":"10.1016\/j.rec.2025.10.016"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Castro Conde, A., Marzal Martin, D., Campuzano Ruiz, R., Fernandez Olmo, M.R., Morillas Arino, C., Gomez Doblas, J.J., Gorriz Teruel, J.L., Mazon Ramos, P., Garcia-Moll Marimon, X., and Soler Romeo, M.J. (2023). Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123925"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"C1150","DOI":"10.1152\/ajpcell.00569.2025","article-title":"Vascular effects of SGLT2 inhibitors: Evidence and mechanisms","volume":"329","author":"Castro","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T15:02:55Z","timestamp":1768489375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020714"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020714","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}